SAB Biotherapeutics (SABS) Other Non-Current Assets (2020 - 2021)
SAB Biotherapeutics (SABS) reported Other Non-Current Assets of $13.1 million for Q4 2021, up 5471.24% on a YoY basis from $235111.0 in Q4 2020, and up 5471.24% quarter-over-quarter from $235111.0 in Q4 2020.
SAB Biotherapeutics (SABS) Other Non-Current Assets (2020 - 2021) Analysis & Trends
SAB Biotherapeutics has reported Other Non-Current Assets for 2 years, with the latest figure at $13.1 million in Q4 2021.
- For the quarter ending Q4 2021, Other Non-Current Assets rose 5471.24% year-over-year to $13.1 million; the trailing twelve-month figure through Dec 2021 stood at $13.1 million (up 5471.24% YoY), and the FY2021 full-year result was $13.1 million, up 5471.24% from the prior year.
- Other Non-Current Assets for Q4 2021 stood at $13.1 million, up from $235111.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $13.1 million in Q4 2021, with the low at $235111.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 13.10 Mn |
| Dec 31, 2020 | 235,111.00 |